Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5Sarcoma 1Lymphoid 1Head & Neck 1Dermatologic 1Breast 1

Conditions

Melanoma 20Breast Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Sarcoma 4Neoplasms 4Urinary Bladder Neoplasms 3Ovarian Neoplasms 3Carcinoma, Merkel Cell 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Skin Neoplasms 2Neoplasm Metastasis 2Lymphoma, T-Cell, Cutaneous 2Lung Neoplasms 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Testicular Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Squamous Cell 1Neoplasms, Plasma Cell 1Mesothelioma 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 10Nivolumab 5Gemcitabine 4durvalumab 3Specimen Handling 3Sirolimus 3Magnetic Resonance Spectroscopy 3Docetaxel 3Cryosurgery 3Cisplatin 3Blood Specimen Collection 3tremelimumab 2temsirolimus 2pertuzumab 2pegilodecakin 2enzalutamide 2cabozantinib 2alvocidib 2Vorinostat 2Trastuzumab 2Ritonavir 2Radiotherapy 2Radiosurgery 2Psychiatric Rehabilitation 2Paclitaxel 2Oxaliplatin 2Interleukin-2 2Cyclophosphamide 2Carboplatin 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × poly ICLC × Dermatologic × Clear all
NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

Phase 1/2 Completed
58 enrolled 24 charts
BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡